Solid biosciences reports second quarter 2024 financial results and provides business updates

– patients dosed in phase 1/2 inspire duchenne trial of sgt-003 for the treatment of duchenne muscular dystrophy (duchenne); dosing was well tolerated in all patients with initial data expected q4 2024 –
SLDB Ratings Summary
SLDB Quant Ranking